About My Health Careers Internship MedBlogs Contact us

Ovarian Cancer Patients may Be Benefited by Investigational Drug

by Rajashri on September 16, 2008 at 4:20 PM
Font : A-A+

 Ovarian Cancer Patients  may Be Benefited by Investigational Drug

New results presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm reveal that women with recurrent ovarian cancer can be helped by giving an investigational drug in combination with chemotherapy.

Dr. Bradley Monk, a UC Irvine gynecologic oncologist who led the worldwide phase III clinical trial, said trabectedin is the most recent addition to a short list of active drug therapies for recurrent ovarian cancer.


"These are exciting results because positive trials in recurrent ovarian cancer are rare and have almost always led to federally approved treatments," said Monk, an associate professor who studies and treats ovarian cancers at the Chao Family Comprehensive Cancer Center at UC Irvine.

"This treatment undoubtedly will be evaluated carefully by the U.S. Food and Drug Administration and, if approved, will give women with ovarian cancer another much needed option," Monk added.

Phase III studies are multicenter trials on large patient groups designed to be the definitive assessment of a drug's effectiveness. Such a study is often the last step before a drug is reviewed by a regulatory agency like the FDA for approval as a safe, effective treatment.

In the latest trial, an international group of researchers treated 672 women whose ovarian cancer had progressed after first-line treatment. Half the women received a combination therapy of trabectedin and a chemotherapy drug called pegylated liposomal doxorubicin.

The other half received the chemotherapy drug alone, which is standard treatment in these cases.

In patients on the combination therapy, researchers found no progression of the cancer for an average of 7.3 months, as compared to 5.8 months for those treated with the single drug.

For those who had relapsed more than six months after the first-line therapy, the median progression-free time was 9.2 months for the combination treatment, as compared to 7.5 months for the other patients.

Trabectedin is a synthetic version of a compound isolated from the sea squirt, a tubular sea animal used in a number of medical studies. It binds to the DNA of a cancer cell and blocks its ability to multiply, thus killing the cells and shrinking tumors.

Source: ANI

News A-Z
News Category
What's New on Medindia
Health Benefits of Sea Buckthorn
Contraceptive Pills in Polycystic Ovary Syndrome (PCOS) Curtail Type 2 Diabetes Risk
Mushroom May Help Cut Down the Odds of Developing Depression
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Ovarian Cancer Cancer and Homeopathy Signature Drug Toxicity Cancer Facts Cancer Meigs Syndrome Ovarian Pain Premature Ovarian Failure Common Lifestyle Habits that Cause Diseases 

Recommended Reading
Women and Cancer
Cancer is one of the frequently talked about and most feared disease that falls under the genre of ....
Hairdressers Face High Cancer Risk from Dyes and Chemicals They Work With
Hairdressers may face an increased risk of cancer because of the dyes and other chemicals they work ...
Common Lifestyle Habits that Cause Diseases
Cigarette smoking, unhealthy diets, overuse of alcohol, and physical inactivity are some of the most...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Meigs Syndrome
Meigs'' syndrome is a medical condition with a triad of symptoms including benign ovarian tumor, asc...
Ovarian Cancer
Ovarian cancer affects both the ovaries and is referred to as the ''silent killer'' as the symptoms ...
Ovarian Pain
Ovarian pain is caused due to various conditions like ovarian cysts, ovarian tumors, endometriosis, ...
Premature Ovarian Failure
Premature menopause is ovarian failure which occurs 2 SD in years before a mean menopausal age and p...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use